Výsledky vyhledávání - "Matthew Ralstin"

Effect of Celecoxib and the Novel Anti-Cancer Agent, Dimethylamino-Parthenolide, in a Developmental Model of Pancreatic Cancer

Autor: Bryan Holcomb, Christopher Sweeney, Michele T. Yip-Schneider, Huangbing Wu, Matthew Ralstin, Sundar Neelakantan, Peter A. Crooks, C. Max Schmidt, Victor Njoku

Publikováno v: Pancreas. 37:e45-e53

Objectives: Cancer of the exocrine pancreas is the fourth leading cause of cancer-related deaths in the United States. The efficacy of a novel bioavailable anticancer agent, dimethylamino-parthenolide (DMAPT), and the cyclooxygenase 2 inhibitor, cele

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6e00f97d84691d7cd4dee40b279dff04
https://doi.org/10.1097/mpa.0b013e318172b4dd

Zobrazit plný text záznamu

Effect of Celecoxib and Novel Agent LC-1 in a Hamster Model of Lung Cancer

Autor: Sundar Neelakantan, Christopher Sweeney, Matthew Ralstin, Harikrishna Nakshatri, Peter A. Crooks, Reid C. Vegeler, Michele T. Yip-Schneider, Huangbing Wu, C. Max Schmidt

Publikováno v: Journal of Surgical Research. 143:169-176

Lung cancer is the leading cause of cancer deaths in the United States. Inflammatory molecules, cyclooxygenase-2 (COX-2) and nuclear factor kappa B (NF-kappaB) have been implicated in lung carcinogenesis. The therapeutic potential of celecoxib, a COX

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0f10df329be652a0936fe16e9854d17c
https://doi.org/10.1016/j.jss.2007.08.007

Zobrazit plný text záznamu

Suppression of pancreatic tumor growth by combination chemotherapy with sulindac and LC-1 is associated with cyclin D1 inhibitionin vivo

Autor: Constantin T. Yiannoutsos, C. Max Schmidt, Peter A. Crooks, Sundar Neelakantan, Matthew Ralstin, Christopher Sweeney, Harikrishna Nakshatri, Michele T. Yip-Schneider, Huangbing Wu, Stephen Noble

Publikováno v: Molecular Cancer Therapeutics. 6:1736-1744

The design of novel targeted or combination therapies may improve treatment options for pancreatic cancer. Two targets of recent interest are nuclear factor-κB (NF-κB) and cyclooxygenase (COX), known to be activated or overexpressed, respectively,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a85ed9abe13b29ee7e31825a26c77066
https://doi.org/10.1158/1535-7163.mct-06-0794

Zobrazit plný text záznamu

Interobserver repeatability of heidelberg retinal flowmetry using pixel-by-pixel analysis

Autor: Brent Siesky, Hanna J. Garzozi, Carlos Rospigliosi, Itay Ben Zion, L. Jay Katz, Alon Harris, Matthew Ralstin, Adam Werne, L. McCranor, Danny Moore, William N. Steinmann

Publikováno v: Journal of glaucoma. 18(4)

PURPOSE To determine the interobserver reproducibility of Heidelberg retinal flowmeter (HRF) blood flow measurements using independently selected study areas for pixel-by-pixel analysis. PATIENTS AND METHODS Blood flow measurements were performed on

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::662a88a4c880c7f6b51340a927142765
https://pubmed.ncbi.nlm.nih.gov/19365191

Zobrazit plný text záznamu

Parthenolide cooperates with NS398 to inhibit growth of human hepatocellular carcinoma cells through effects on apoptosis and G0-G1 cell cycle arrest

Autor: Matthew Ralstin, Patrick J. Klein, Earl A. Gage, Eric A. Wiebke, C. Max Schmidt, Michele T. Yip-Schneider

Publikováno v: Molecular cancer research : MCR. 4(6)

Chemotherapy to date has not been effective in the treatment of human hepatocellular carcinoma. More effective treatment strategies may involve combinations of agents with activity against hepatocellular carcinoma. Parthenolide, a nuclear factor-κB

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6d5e7628ce0f8da7805c149cdad7bbd6
https://pubmed.ncbi.nlm.nih.gov/16778086

Zobrazit plný text záznamu